Last reviewed 2026-05-21 · How we verify

Verdia (TASOSARTAN)

Phase 2 active Small molecule Under review Quality 10/100

Verdia (generic name: TASOSARTAN) is a tasosartan drug. It is currently in Phase 2 development for Hypertensive disorder.

Verdia works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure.

Verdia is a small molecule that acts as a Type-1 angiotensin II receptor antagonist. It is classified as an antagonist and has synonyms including ANA-756, TASOSARTAN, and WAY-ANA-756.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TASOSARTAN
Drug class	tasosartan
Target	Type-1 angiotensin II receptor
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Think of it like a traffic light: angiotensin II is like a red light that tells blood vessels to constrict and blood pressure to rise. Verdia blocks this red light, allowing blood vessels to relax and blood pressure to decrease. This helps to lower blood pressure and reduce the risk of heart disease.

Approved indications

Hypertensive disorder

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Verdia CI brief — competitive landscape report
Verdia updates RSS · CI watch RSS

Frequently asked questions about Verdia

What is Verdia?

Verdia (TASOSARTAN) is a tasosartan drug, indicated for Hypertensive disorder.

How does Verdia work?

Verdia works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure.

What is Verdia used for?

Verdia is indicated for Hypertensive disorder.

What is the generic name of Verdia?

TASOSARTAN is the generic (nonproprietary) name of Verdia.

What drug class is Verdia in?

Verdia belongs to the tasosartan class. See all tasosartan drugs at /class/tasosartan.

What development phase is Verdia in?

Verdia is in Phase 2.

What does Verdia target?

Verdia targets Type-1 angiotensin II receptor and is a tasosartan.

Drug class: All tasosartan drugs
Target: All drugs targeting Type-1 angiotensin II receptor
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Hypertensive disorder

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing